The agreement allows Jubilant access to DiscoveRx PathHunter and cAMPHunter cell lines and proprietary EFC chemiluminescent detection technology to perform screening on behalf of Jubilant’s customers.
The company claims that PathHunter ss-Arrestin and HitHunter cAMP assays are homogeneous chemiluminescent assays which are rapidly becoming GPCR screening platform of choice for screening and profiling applications.
Kailash Swarna, COO of global drug discovery at Jubilant Biosys, said: “We are pleased to announce this agreement with DiscoveRx, and look forward to the prospect of providing value to our customers using DiscoveRx PathHunter and HitHunter technologies.
Pyare Khanna, president and CEO, DiscoveRx, said: “DiscoveRx constantly strives to provide our solutions to screening community. We are determined to help expedite the drug discovery processes and are delighted with this relationship with Jubilant. Our customers require an easy access to our innovative product portfolio and such partnerships will add value to our efforts of bringing industry leading portfolio of PathHunter and HitHunter GPCR assays to a broader audience.”